title: Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).
abstract: Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART.
authors.affiliation: Department of Internal Medicine, Medical Clinic C, Ludwigshafen, Germany. J.Teichmann@st.josefskrankenhaus.de
authors.forename: J
authors.initials: J
authors.lastname: Teichmann
authors.forename: U
authors.initials: U
authors.lastname: Lange
authors.forename: T
authors.initials: T
authors.lastname: Discher
authors.forename: J
authors.initials: J
authors.lastname: Lohmeyer
authors.forename: H
authors.initials: H
authors.lastname: Stracke
authors.forename: R G
authors.initials: RG
authors.lastname: Bretzel
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000378:metabolism; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000453:epidemiology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism; D015995:Prevalence; D013739:Testosterone / Q000097:blood / Q000378:metabolism; D055815:Young Adult
chemical_list: D010281:Parathyroid Hormone; D015675:Osteocalcin; D013739:Testosterone